EADV
Beyond's analysis on EADV
- — AbbVie's Phase 2 trial shows its experimental drug zumilokibart significantly improves eczema symptoms versus placebo, advancing a potential new atopic dermatitis therapy
- — Avalo Therapeutics scheduled to present clinical data at the EADV 2026 Congress
Recent news mentioning EADV
- — AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
- — AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
- — Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
- — Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
- — Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV Congress
- — LeadVenture® names Nasi Jazayeri Chief Executive Officer
- — McKendree Hickory Claims Women's Title in Her Debut at Life Time Leadville Trail 100 Run as Adrian Macdonald Wins Third Men's Victory
- — Keegan Swenson Ties the All-Time Record at the 32nd Annual Life Time Leadville Trail 100 MTB presented by Kenetik